New York, NYNCT04239079Now EnrollingIRB Ready

Parkinson Disease Clinical Trial in New York, NY

Access cutting-edge parkinson disease treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Columbia University

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access parkinson disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related parkinson disease treatment provided free

Apply for This New York Location

Check if you qualify for this parkinson disease clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Parkinson Disease Study in New York

This study is being conducted to better understand the role of inflammation in Parkinson's disease (PD) and Alzheimer's disease (AD). The investigators plan to recruit 30 PD, 30 AD/Amnestic Mild Cognitive Impairment (aMCI), and 60 age matched healthy controls in this study to study the role of immune response in PD and AD. The study involves up to two study visits involving brief questionnaires and blood draw of up to 250cc (approximately 17 tablespoons) to be collected. More ways to participate, including 1) smaller amount blood donation (up to 100cc per visit for 1-2 visits); and 2) participation via tele-visit and mobile phlebotomy visits (blood donation up to 50cc, \~5 tubes, by a certified mobile phlebotomist at home/location of choice) now available.

Sponsor: Columbia University

Who Can Participate

Inclusion Criteria

Clinical diagnosed PD based on UK Brain Bank criteria for the clinical diagnosis of PD. And must demonstrate two of the following three, as modified from BioFIND criteria: rest tremor, rigidity, or bradykinesia, with dopaminergic medication benefit
Age at recruitment ≥ 55
Age at motor onset \> 45
PD onset age between 50-75 years
Willingness to have genotyping and genetic studies

Exclusion Criteria

Atypical features indicative of a Parkinson-Plus disorder (Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), Corticobasal Degeneration (CBD)) including cerebellar signs, supranuclear gaze palsy, apraxia and other cortical signs, or prominent autonomic failure, neuroleptic treatment at time of onset of parkinsonism, active treatment with a neuroleptic at time of study entry, history of repeated strokes with stepwise progression of parkinsonism, history of repeated head injury, history of definite encephalitis, prominent gait imbalance early in the course (\< 5 years)
History of Dementia
Recent history of cancer (past 3 years), except skin cancer
Autoimmune disease
Disease of the immune system (e.g. chronic leukemia, HIV)
On chronic immune-modulatory therapy (e.g. oral steroids, azathioprine, rituximab)
Inability to provide informed consent. For age-matched control participants (n=30): Inclusion criteria:
Ages ≥55 years old
With lack of PD in first-degree blood relatives
Montreal Cognitive Assessment (MoCA): ≥26
Willingness to have genotyping and genetic studies Exclusion criteria:
Recent history of cancer (past 3 years), except skin cancer
Autoimmune disease
Disease of the immune system (e.g. chronic leukemia, HIV)
On chronic immune-modulatory therapy (e.g. oral steroids, azathioprine, rituximab)
Inability to provide informed consent AD/aMCI and age matched controls: For AD/aMCI participants (n=30): Inclusion criteria:
Clinically diagnosed mild AD/amnestic MCI. The severity will be accessed through the Clinical Dementia Rating Scale (CDR). CDR equal to 0.5 or 1 will be necessary to meet criteria. Participants with advanced AD stage will not be capable to give their consent.
Age ≥55 years old
Mini-Mental State Exam (MMSE): 20-26
Willingness to have genotyping and genetic studies Exclusion criteria:
Other forms of dementia including frontotemporal dementia or other dementia associated with parkinsonism such as Dementia with Lewy bodies (DLB), or Parkinson's disease Dementia (PDD), Progressive Supranuclear Palsy or corticobasal degeneration.
History of Parkinson's disease (PD)
Recent history of cancer (past 3 years), except skin cancer
Autoimmune disease
Disease of the immune system (e.g. chronic leukemia, HIV)
On chronic immune-modulatory therapy (e.g. oral steroids, azathioprine, rituximab)
Inability to provide informed consent For age-matched control participants (n=30): Inclusion criteria:
Healthy volunteers ≥55 years old
Willingness to have genotyping and genetic studies Exclusion criteria:
History of Parkinson's disease (PD)
Recent history of cancer (past 3 years), except skin cancer
Autoimmune disease
Disease of the immune system (e.g. chronic leukemia, HIV)
On chronic immune-modulatory therapy (e.g. oral steroids, azathioprine, rituximab)
Inability to provide informed consent

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT04239079) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Parkinson Disease Treatment Options in New York, NY

If you're searching for parkinson disease treatment options in New York, NY, this clinical trial (NCT04239079) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced parkinson disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all parkinson disease clinical trials near you to find additional studies recruiting in your area.

More Parkinsons Disease Trials in New York, NY

See all parkinsons disease clinical trials recruiting in New York — not just this study.

Browse Parkinsons Disease Trials in New York →

Browse More Trials by Condition

Parkinsons Disease TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY